According to the Centers for Disease Control and Prevention (CDC), the US government will allocate approximately 85% fewer doses of Johnson & Johnson’s Covid-19 vaccine to states next week due to uneven production, partly a result of issues at a Baltimore manufacturing facility. The week’s allocation is expected to drop to 785,500 doses from 4.95 million doses, although this data does not include allocations to a federal retail pharmacy programme.
Eli Lilly and Incyte have announced results from the Phase III COV-BARRIER study of baricitinib 4mg for treating hospitalised Covid-19 patients. The study did not meet statistical significance in 1,525 patients, although data revealed a 38% fall in deaths by the 28th day among patients treated with baricitinib along with standard-of-care treatment, including corticosteroids and/or remdesivir. Patients receiving baricitinib were 2.7% less likely to progress to ventilation or death, a difference that was not statistically significant.
The Institute of Public Health of Chile has granted emergency use approval to CanSinoBIO’s single-dose Covid-19 recombinant vaccine, Convidecia. It is the first single-dose vaccine to be approved for emergency use in Chile, and the first approval of Convidecia in South America. Interim Phase III trial results suggest the vaccine is 65.28% effective at preventing symptomatic Covid-19 28 days after dosing, with an efficacy rate of 90.07% in preventing severe illness 28 days after the single-dose vaccination.